Radioactive treatment for stubborn neuroblastoma
Part of Cancer clinical trials.
This trial uses a radioactive medicine called MIBG to target and kill neuroblastoma or related tumor cells that have not responded to standard treatments. It may help patients whose cancer has come back or is hard to treat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have neuroblastoma or a related tumor that has returned or not responded to standard treatments.
- Your tumor shows up on a special scan (MIBG scan) within 6 weeks before joining.
- You are older than 1 year and can follow safety rules for radiation.
- You have a performance status of 60% or higher, meaning you can do most daily activities.
- You have stored stem cells (from your own body) available for a possible transplant after treatment, or your doctor agrees to a lower dose.
- Your liver, kidney, blood counts, lungs, and heart are working well enough, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for children or young adults already in specific brain tumor or neuroblastoma trials. It looks at how a type of imaging (MCT) might help doctors better understand and treat these cancers.
This trial gives a radioactive drug called 131-I-MIBG to treat neuroblastoma that has not gone away or has come back. The drug targets cancer cells, and stem cells are given back after treatment to help the body recover.
This trial uses a radioactive medicine called 131I-MIBG to treat neuroblastoma or pheochromocytoma that has come back or not responded to standard treatment. The treatment targets and damages cancer cells while trying to spare healthy tissue.
This trial provides access to a radioactive medicine called 131I-MIBG for people with certain nerve tumors that have returned or not responded to standard treatment. The treatment targets and kills cancer cells, and it may help when other options have not worked.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This trial tests a combination of targeted radiation (MIBG) with two medicines, vorinostat and dinutuximab, for children and young adults with high-risk neuroblastoma that has returned or not fully responded to earlier treatment. The goal is to see if adding these medicines helps the radiation work better and improves outcomes.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.